Evidence map›Paper›PMID 41586519›Full record

ArticlemBio2026

The Dp16 Down syndrome mouse model does not exhibit oral interferon-gammopathy or susceptibility to oral candidiasis.

Ashira Lubkin, Ramon A Lujan, Sergio M Pontejo, Vasileios Oikonomou, Abigail M Fellows, Lucas Dos Santos Dias, Brendan D Snarr, Jessie MacAlpine, Kelly D Sullivan, Joaquin M Espinosa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ashira LubkinFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0002-0271-0562
Ramon A LujanViral Immunity and Pathogenesis Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA.
Sergio M PontejoMolecular Signaling Section, Laboratory of Molecular Immunology, NIAID, NIH, Bethesda, Maryland, USA.ORCID 0000-0002-7756-9831
Vasileios OikonomouFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Abigail M FellowsFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Lucas Dos Santos DiasFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Brendan D SnarrFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Jessie MacAlpineFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Kelly D SullivanLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, Colorado, USA.
Joaquin M EspinosaLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, Colorado, USA.
Heather HickmanViral Immunity and Pathogenesis Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, Maryland, USA.ORCID 0000-0003-4168-4894
Michail S LionakisFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0003-4994-9500

Funding

Postdoctoral Research Associate Training Program (PRAT)ZIEGM000002 · NIGMS · NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES · PI NELSON, SHAKIRA · 2009 to 2025
$31.7M
Intramural NIH HHS ZIE GM000002
6 · The paper itself

Abstract

Down syndrome, or Trisomy 21, is associated with excessive interferon (IFN) signaling and concomitant susceptibility to both autoimmunity and immunodeficiency. One of the many clinical phenotypes observed in people with Down syndrome is increased risk for oral candidiasis. Because oral candidiasis can be caused by excessive IFN-γ signaling, we asked whether IFN-gammopathy could be playing a role in susceptibility to oral candidiasis in Down syndrome. We used the Dp16 mouse model of Down syndrome, which displays mild systemic interferonopathy, to model oral candidiasis. We found that the Dp16 model does not exhibit oral IFN-gammopathy and is not susceptible to oral candidiasis. We exposed the Dp16 mice to various inflammatory and infectious stimuli with the goal to induce enhanced local IFN-γ responses, but these did not induce oral IFN-gammopathy or promote susceptibility to oral candidiasis. We conclude that the Dp16 model is not well-suited to study oral IFN-gammopathy or oral candidiasis. Clinical studies of oral candidiasis in people with Down syndrome are warranted.IMPORTANCEDown syndrome, caused by three copies of chromosome 21, presents with different medical conditions in different people. One such condition for some people with Down syndrome is increased susceptibility to oral infection with the fungus

Indexed as

Candidiasis, OralDown SyndromeInterferon-gammaInterferonsAnimalsCandida albicansDisease Models, AnimalDisease SusceptibilityFemaleMiceInterferon-gammaInterferonsCandida albicansDown syndromeinterferon-gammopathyoral candidiasis

Identifiers

PMID41586519
PMCPMC12977504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.